What Canary Foundation does

Canary Foundation is a 501(c)(3) nonprofit research organization founded in 2004 by Don Listwin following his mother's death from late-stage ovarian cancer, and is the world's first and only nonprofit dedicated solely to early cancer detection. It funds and conducts research across five solid-tumor cancer types — breast, lung, ovarian, pancreatic, and prostate — through a two-pronged technological platform combining blood-based biomarker discovery (validated assets include HE4 for ovarian cancer and a 2017 lung cancer biomarker) with molecular imaging (FDA-approved microbubble ultrasound, photoacoustic imaging, and an on-site cyclotron producing 36+ FDA-approved radiotracers). Its anchor institution is the Canary Center at Stanford, established in 2009 with a $50M commitment, and it operates a multi-center clinical platform anchored by the PASS study (2,400+ prostate cancer active surveillance participants across 13+ sites) and the 2023-launched PATROL genetic-risk cohort.

The foundation's go-to-market is community- and event-led rather than commercial: it convenes the annual Early Detection of Cancer Conference (EDx, co-hosted with CRUK and OHSU), seeds postdoctoral fellowships (Canary-ACS, Phillips), and channels discoveries through licensing relationships with diagnostics companies including Fujirebio, Exact Sciences, OPKO Health, Gen-Probe/Hologic, Abbott Diagnostics, and Bracco. Revenue comes from philanthropic donations, government grants (NCI/NIH/EDRN), and licensing royalties, with 91% of every donated dollar going to cancer research programs and 2020 total funds raised of approximately $3M against a cumulative $75M+ raised since inception. It serves academic medical centers (Stanford, Fred Hutch, MD Anderson, UCSF, Cambridge), diagnostics industry partners, and underserved community health partners (Baywell Health), while increasingly extending its mission beyond oncology into precision treatment for neurology, cardiology, and autoimmune conditions.

The organization is intentionally lean — approximately five core staff — with Don Listwin as Founder, Chairman & CEO and a small Leadership Council of venture capital partners and philanthropists. Its core AI/technology layer includes the Canary Quantum Cloud (launched 2015) for ML-driven biomarker discovery and AI-enhanced imaging analysis, but AI functions as an applied tool within a biology- and clinical-data-led research portfolio rather than as the primary value driver.

Name

Canary Foundation

Legal name

Canary Foundation

Website

https://canaryfoundation.org

Company type

Private

Founded year

2004

Operating status

Operating

Headcount range

1–10 employees

Short description

Canary Foundation is the world's first nonprofit dedicated solely to early cancer detection, funding biomarker and molecular imaging research across five cancer types. It operates the Canary Center at Stanford, the PASS and PATROL clinical studies, and translates discoveries through partnerships with leading academic centers and diagnostics companies.

Ownership category

akta.pro rank

Product category

Nonprofit Cancer Research Foundation

NAICS

Grantmaking Foundations (813211), Testing Laboratories and Services (541380)

SIC

Services-Commercial Physical & Biological Research (8731), In Vitro & In Vivo Diagnostic Substances (2835), Services-Testing Laboratories (8734)

akta.pro primary industry

Research & Science Grantmaking Foundations (BPAGAKAI)

Keywords

• Cancer early detection
• Biomarker discovery
• Molecular imaging
• Cancer research funding
• Clinical research programs

Headquarters

HQ city

Palo Alto

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Operations, Marketing or Sales, Personnel, Others

Revenue model

1. Philanthropic Donations: Canary Foundation is a 501(c)(3) nonprofit organization funded primarily through charitable donations from individuals, foundations, and corporate partners. Donations support the full spectrum of early cancer detection research programs.
2. Government Research Grants: Funding from government agencies including the National Cancer Institute (NCI), National Institutes of Health (NIH), and the Early Detection Research Network (EDRN) for specific research programs including the PASS study and biomarker discovery.
3. Corporate Partnerships and Licensing: Industry partnerships with companies including Fujirebio (HE4 biomarker commercialization), OPKO Health, Exact Sciences, Gen-Probe/Hologic, and Abbott Diagnostics provide research support and generate licensing interest. Technology spinouts from foundation-funded research represent potential future revenue.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

Core offering

Canary Foundation is a 501(c)(3) nonprofit that funds, discovers, and develops early cancer detection tests through collaborative research. It operates biomarker discovery programs, molecular imaging research (including FDA-approved microbubble ultrasound), and multi-center clinical studies (PASS, PATROL), translating discoveries into commercial diagnostics through licensing partnerships with companies such as Fujirebio and Exact Sciences.

Product overview

Canary Foundation is a nonprofit research organization (not a product company) dedicated solely to funding, discovery, and development of tests for early cancer detection. The foundation operates research programs across five cancer types (breast, lung, ovarian, pancreatic, and prostate) through multidisciplinary teams and strategic partnerships. Its portfolio includes the Prostate Active Surveillance Study (PASS) with over 2,400 participants, the PATROL genetic risk study, and various imaging technologies including FDA-approved microbubble ultrasound capable of detecting tumors below 1mm. The foundation supports biomarker research including validated HE4 and CA-19-9 biomarkers, operates the Canary Center at Stanford as its anchor institution, and collaborates with academic and industry partners to translate discoveries into clinical applications.

Differentiator

Problem solved

Functional benefit

Products and services

• Prostate Active Surveillance Study (PASS) Multi-center clinical study monitoring over 2,400 men with low-risk prostate cancer to optimize treatment timing and avoid unnecessary interventions, directly influencing national screening guidelines. Conducted with research partners including Fred Hutchinson Cancer Center (coordinating center), Stanford Cancer Institute, UCSF, University of Washington, and University of Pennsylvania.
• PATROL Study Prostate Cancer Screening for People at Genetic Risk for Aggressive Disease, focusing on genetic risk cohort identification and biobanking for early detection in high-risk populations. Targets individuals with elevated genetic predisposition to aggressive prostate cancer.
• Microbubble Ultrasound Technology FDA-approved enhanced ultrasound imaging technology using targeted microscopic gas bubbles to enable detection of pancreatic tumors smaller than 1mm with 10,000x greater sensitivity than standard tests. Developed through research at the Canary Center at Stanford and partnered with Bracco for clinical trials.
• Photoacoustic Imaging (PAI) Non-invasive imaging technique combining laser light and ultrasound to create detailed images of blood vessels and tissues, revealing tumor blood supply and molecular signatures for cancer detection.
• Liquid Biopsy Center Research program using non-invasive blood, urine, interstitial fluid, and exosome analysis — including microneedle patch technology — to detect cancer at earliest stages. The center identified 149 proteins in normal urine samples, enabling non-invasive cancer detection research.
• HE4 Biomarker Validated ovarian cancer biomarker discovered through Canary-funded research; licensed to Fujirebio and now FDA-cleared in the U.S. as an aid in monitoring recurrence or progressive disease in patients with epithelial ovarian cancer.
• CA-19-9 Biomarker Pancreatic cancer blood biomarker being enhanced through combination with imaging and other biomarkers for more accurate early detection of pancreatic cancer.
• Cyclotron & Radiochemistry Facility On-site cyclotron facility at the Canary Center at Stanford producing over 36 FDA-approved radiotracers for molecular imaging research, preclinical research, and clinical applications.
• Canary Center at Stanford World-class research facility established in 2009 and dedicated to early cancer detection, integrating in vivo and in vitro diagnostics with molecular imaging, proteomics, chemistry, and bioinformatics. The anchor institution for Canary Foundation's research program; moved to Stanford Technology and Innovation Park in 2013, doubling laboratory space.

Quantifiable outcome

• HE4 biomarker validated and now used clinically worldwide for ovarian cancer detection and monitoring
• +4 more outcomes

Named customers13 records

Segments4 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability7 records

Feature7 records

Partnerships

24 partnerships are on record, tiered core, major and minor.

• Canary Center at Stanford / Stanford School of MedicinecoreStrategic or Co-development PartnerEstablished in 2009 with a $10 million investment from Don Listwin/Canary Foundation. First integrated diagnostic center for cancer early detection combining in vivo and in vitro diagnostics, molecular imaging, proteomics, chemistry, and bioinformatics. Co-led by Dr. Sanjiv Sam Gambhir (1962–2020) and currently directed by Joseph M. DeSimone, PhD. The anchor institution for Canary Foundation's research.
• Fred Hutchinson Cancer Center (FHCC)coreStrategic or Co-development PartnerThe genesis institution for Canary Foundation. Don Listwin's $10 million investment helped establish the biomarker discovery and analysis program. Dr. Nicole Urban's ovarian cancer biomarker research was the first Canary-funded work (2002). Houses PASS data management, coordinating center, and central biospecimen repository. Dr. Lee Hartwell (Nobel Laureate) was founding partner.
• Cancer Research UK (CRUK)coreStrategic or Co-development PartnerInternational collaboration partner for the Early Detection of Cancer Conference (EDx). CRUK co-hosts the annual conference with Canary Center at Stanford and OHSU Knight Cancer Center, representing a major international partnership in the early detection field.
• OHSU Knight Cancer CentercoreStrategic or Co-development PartnerPartnership with Oregon Health & Science University for the annual Early Detection of Cancer Conference (EDx25 held October 21–23, 2025 in Portland, Oregon). Co-host of the international conference focused on advancing early detection research.
• MD Anderson Cancer CentercoreStrategic or Co-development PartnerHouston-based partner for prostate cancer and lung cancer early detection research. Leading collaborative study for lung cancer biomarkers to reduce false positive screening and increase early detection rates. Partner in multi-site lung cancer biomarker trial enrolling 10,000+ individuals.
• Cambridge UniversitymajorStrategic or Co-development PartnerInternational research collaboration partner in the early detection field. Part of global network of research institutions working on cancer early detection technologies and sample sharing.
• University of California, San Francisco (UCSF)majorStrategic or Co-development PartnerPASS study site and Canary high grade serous cancer (HGSC) initiative for ovarian cancer research. Collaborates on biomarker discovery and validation studies.
• University of WashingtonmajorStrategic or Co-development PartnerPASS study site and support for ovarian and pancreatic cancer teams. Provides clinical research infrastructure for multi-center studies.
• University of PennsylvaniamajorStrategic or Co-development PartnerPASS study site for HGSC initiative for ovarian cancer. Supports ovarian cancer team research with focus on high-grade serous carcinoma origins.
• Early Detection Research Network (EDRN) of NCImajorStrategic or Co-development PartnerAn initiative of the National Cancer Institute bringing together dozens of institutions to accelerate the translation of biomarker information into clinical applications. EDRN provides statistical and data management support for the Canary Prostate Cancer Active Surveillance Study (PASS).
• BC Cancer AgencymajorStrategic or Co-development PartnerCanary Foundation set up and supported a facility at the Deeley Research Center in Victoria, British Columbia, to generate reagents to test candidate biomarkers for lung, pancreatic, prostate, and ovarian cancer. Jointly manages the antibody and hybridoma resource.
• FujirebiocoreOEM/ Whitelabel/ Licensing PartnerFujirebio commercialized the HE4 biomarker discovered in conjunction with Canary's ovarian cancer team research. HE4 is now cleared in the U.S. as an aid in monitoring recurrence or progressive disease in patients with epithelial ovarian cancer.
• OPKO HealthmajorTechnology or IntegrationCanary Prostate cancer team partners with OPKO Health to test blood-based biomarkers in the Canary Prostate Active Surveillance Study (PASS) participants.
• Exact Sciences (formerly GHI)majorTechnology or IntegrationCanary prostate cancer team partnered with Exact Sciences to test a tissue-based biomarker panel for risk stratification in PASS study participants.
• Gen-Probe/HologicmajorTechnology or IntegrationCanary Prostate cancer team partnered with Gen-Probe/Hologic to test urine-based biomarkers in Canary PASS participants for early prostate cancer detection.
• Abbott DiagnosticsmajorTechnology or IntegrationCanary Foundation worked with Abbott Diagnostics to support testing of blood-based biomarkers in women participating in the Novel Markers Trial for ovarian cancer.
• BraccomajorTechnology or IntegrationCanary Foundation researchers worked in partnership with Bracco to enter contrast enhanced ultrasound techniques into U.S. clinical trials for early cancer detection.
• The Lustgarten FoundationmajorStrategic or Co-development PartnerPartnership for pancreatic cancer research to develop a joint set of blood-based biomarkers for research and early detection testing. Work to generate tests for 60 pancreatic cancer biomarkers was completed in 2010.
• American Cancer SocietymajorStrategic or Co-development PartnerIn 2005, Canary and the American Cancer Society partnered to provide postdoctoral research fellowships to scientists in early cancer detection. The program continued until 2011.
• Uniting Against Lung CancerminorStrategic or Co-development PartnerIn 2010, Canary partnered with Uniting Against Lung Cancer in an initiative to find biomarkers in people who have never smoked, supporting lung cancer research in never-smoker populations.
• Baywell HealthminorStrategic or Co-development PartnerCommunity partnership with Baywell Health in Oakland, serving the Black community for 50 years with expanded lung cancer screening programs and education to address health disparities.
• Teal HealthminorStrategic or Co-development PartnerPartnership for at-home self-collect cervical cancer screening with primary HPV testing, overcoming discomfort and access barriers. Founded by Avnesh Thakor, with Joseph M. DeSimone on Board of Directors.
• ACED Alliance (International Alliance for Cancer Early Detection)coreStrategic or Co-development PartnerLaunched in 2019, the ACED Alliance is The International Alliance for Cancer Early Detection, bringing together leading institutions for global coordination and collaboration in early detection research.
• BRCA FoundationmajorStrategic or Co-development PartnerPartnership launched in 2018 for ovarian cancer prevention initiative. Collaborates on BRCA pre-cancer atlas development and prevention strategies for high-risk populations.

Scale indicators11 records

Recent moves9 records

Expansion highlights6 records

Broad incumbents

• American Cancer Society: The American Cancer Society is the largest U.S. nonprofit cancer organization, a broad incumbent in cancer research funding and patient services. Canary partnered with ACS for postdoctoral fellowships (2005-2011), and they overlap in grantmaking and public cancer education.
• Susan G. Komen: Susan G. Komen is a major nonprofit funding breast cancer research, awareness, and patient support. It is comparable as a cancer-specific grantmaking foundation with similar donor-driven funding model and translational research goals.

Direct peers

• Stand Up To Cancer: Stand Up To Cancer is a major U.S. charitable program funding collaborative cancer research teams, directly comparable to Canary as a peer nonprofit that raises philanthropic donations and grants them to academic research teams to accelerate cancer breakthroughs.
• Lustgarten Foundation: Lustgarten Foundation is the largest private funder of pancreatic cancer research in the U.S., directly comparable as a disease-focused cancer research foundation. Canary has partnered with Lustgarten on pancreatic biomarker work, confirming peer status.
• V Foundation for Cancer Research: The V Foundation funds cancer research through grants to investigators, similar to Canary's grantmaking model. It serves comparable donor audiences and supports similar academic cancer research, with overlapping translational research goals.
• Prevent Cancer Foundation: The Prevent Cancer Foundation is dedicated to early detection and prevention of cancer, the most direct thematic peer to Canary Foundation. Both focus on cancer screening, early detection research, and public education.
• Damon Runyon Cancer Research Foundation: Damon Runyon is a leading cancer research grantmaking foundation funding high-impact innovative research, comparable to Canary's mission-driven grantmaking model with similar donor demographics and fellowship programs.
• Cancer Research UK: Cancer Research UK is the world's largest independent cancer research charity, co-hosting the EDx conference with Canary. It serves as an international peer in cancer research grantmaking, biomarker development, and clinical translation.
• Gateway for Cancer Research: Gateway for Cancer Research funds early-phase clinical cancer trials and translational research. Comparable to Canary in funding investigator-initiated cancer research with similar grantmaking discipline and translational focus.
• National Foundation for Cancer Research: NFCR is a nonprofit that funds cancer research globally with a focus on translational science and early-stage innovation, providing a peer grantmaking model and donor base similar to Canary Foundation's research-focused approach.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/@canaryfoundation/videos
• LinkedInlinkedin.com/company/canary-foundation

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Canary Foundation